Ascendis Pharma A (ASND) Income towards Parent Company (2016 - 2025)
Historic Income towards Parent Company for Ascendis Pharma A (ASND) over the last 12 years, with Q4 2025 value amounting to -$39.6 million.
- Ascendis Pharma A's Income towards Parent Company rose 356.67% to -$39.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$166.8 million, marking a year-over-year decrease of 15086.67%. This contributed to the annual value of -$261.7 million for FY2025, which is 3522.58% up from last year.
- According to the latest figures from Q4 2025, Ascendis Pharma A's Income towards Parent Company is -$39.6 million, which was up 356.67% from -$73.1 million recorded in Q3 2025.
- Over the past 5 years, Ascendis Pharma A's Income towards Parent Company peaked at $176.6 million during Q3 2023, and registered a low of -$211.6 million during Q4 2022.
- Moreover, its 5-year median value for Income towards Parent Company was -$74.4 million (2025), whereas its average is -$28.9 million.
- Per our database at Business Quant, Ascendis Pharma A's Income towards Parent Company tumbled by 25224.72% in 2023 and then skyrocketed by 21873.17% in 2024.
- Over the past 5 years, Ascendis Pharma A's Income towards Parent Company (Quarter) stood at -$121.3 million in 2021, then crashed by 74.41% to -$211.6 million in 2022, then skyrocketed by 55.07% to -$95.1 million in 2023, then skyrocketed by 56.77% to -$41.1 million in 2024, then rose by 3.57% to -$39.6 million in 2025.
- Its Income towards Parent Company was -$39.6 million in Q4 2025, compared to -$73.1 million in Q3 2025 and $45.6 million in Q2 2025.